The novel, orally available and peripherally restricted selective cannabinoid CB₂ receptor agonist LEI‐101 prevents cisplatin‐induced nephrotoxicity

Abstract

These results indicate that LEI-101 is a selective, largely peripherally restricted, orally available CB2 receptor agonist with therapeutic potential in diseases that are associated with inflammation and/or oxidative stress, including kidney disease.